Manipal Health Enterprises has launched its ₹9,275 crore IPO, consisting of an ₹8,000 crore fresh issue and a ₹1,275 crore offer for sale. The hospital chain, valued at ₹77,606 crore, plans to use a large portion of the proceeds to cut its ₹10,230 crore net debt. Investors may track its ability to integrate recent acquisitions like Sahyadri Hospitals and manage its debt levels.
Manipal Health Enterprises, one of India’s largest private hospital networks, has officially opened its initial public offering (IPO) for subscription today, July 29, 2026. The issue, which remains open until July 31, seeks to raise a total of ₹9,275 crore. This capital is split between a fresh issuance of equity shares worth ₹8,000 crore and an offer for sale (OFS) of existing shares valued at ₹1,275 crore. Upon listing, the company is expected to command a total market capitalization of ₹77,606 crore.
Debt Reduction and Acquisition Strategy
A central focus for investors is the company’s current debt position. As of March 31, 2026, Manipal Health reported a net debt of ₹10,230 crore, which reflects a net debt-to-EBITDA ratio of 3.9 times. This elevated leverage is largely due to its aggressive expansion strategy, including the recent acquisition of Sahyadri Hospitals for ₹5,000 crore in October 2025. The company intends to allocate approximately ₹5,500 crore from the fresh issue proceeds toward paying down existing debt. This move is designed to improve the company's financial flexibility and interest coverage ratios. Analysts note that while this debt reduction is a positive step, the successful integration of multiple acquisitions, including Columbia Asia and AMRI Hospitals, will be a key factor for operational performance in the coming years.
Financial Growth and Valuation Context
Manipal Health has seen significant growth, with revenues reaching ₹10,335 crore in FY26. The company’s revenue and profit have grown at a compound annual growth rate of 29% and 31%, respectively, over the past three years. Its EBITDA margins have stayed consistently in the 25% to 27% range, which compares favorably within the Indian hospital sector. At its current valuation, the company trades at 31 times its Enterprise Value to EBITDA (EV/EBITDA), representing a slight discount compared to the 35 times multiple commanded by industry peer Apollo Hospitals. Because Apollo is an established listed player with a longer public track record, some market observers are waiting for more clarity on Manipal Health’s post-listing performance before assessing its long-term valuation premium.
Operational Outlook and Future Capacity
The company is focused on increasing its licensed bed capacity from 13,037 as of March 2026 to 15,463 by FY30. While this expansion is significant, it is a slower pace of capacity addition than some competitors like Apollo and Medanta. To maintain its competitive edge, the company is placing emphasis on an 'advanced case mix'—which includes complex procedures in cardiac, oncology, and neurosciences—now accounting for 64% of its work. Future success will likely depend on its ability to improve operational efficiency through these complex medical cases and the integration of new technology like robotic surgery. Investors should continue to monitor upcoming quarterly reports to see if the company successfully reduces its debt burden and maintains these margins while scaling its hospital infrastructure.